Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Monica N, Fornier"'
Autor:
Veronica Mariotti, David B. Page, Oksana Davydov, Didier Hans, Clifford A. Hudis, Sujata Patil, Siddharth Kunte, Monica Girotra, Azeez Farooki, Monica N. Fornier
Publikováno v:
Journal of Bone Oncology, Vol 7, Iss C, Pp 32-37 (2017)
Introduction: Aromatase-inhibitors (AIs) are commonly used for treatment of patients with hormone-receptor positive breast carcinoma, and are known to induce bone density loss and increase the risk of fractures. The current standard-of-care screening
Externí odkaz:
https://doaj.org/article/1b98a1d4536a4a2384fe89b89ca5f1d3
Autor:
Andrew J. Dannenberg, Clifford A. Hudis, Monica N. Fornier, Shanu Modi, Chau T. Dang, Laura C. Hawks, Daniel Goldstein, Ginger L. Milne, Xi Kathy Zhou, Patrick G. Morris
PDF file - 76K, Additional Patient Characteristics.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::708df252c460e7f3d73491a8230563aa
https://doi.org/10.1158/1940-6207.22523506.v1
https://doi.org/10.1158/1940-6207.22523506.v1
Autor:
Andrew J. Dannenberg, Clifford A. Hudis, Monica N. Fornier, Shanu Modi, Chau T. Dang, Laura C. Hawks, Daniel Goldstein, Ginger L. Milne, Xi Kathy Zhou, Patrick G. Morris
Supplementary Data from Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04388f6864d580b2bd90f32091b8d20f
https://doi.org/10.1158/1940-6207.22523509.v1
https://doi.org/10.1158/1940-6207.22523509.v1
Autor:
Shanu Modi, Sarat Chandarlapaty, Nancy T. Sklarin, Monica N. Fornier, Neal Rosen, Sujata Patil, Alexia Iasonos, Fanni Ratzon, Fresia Pareja, Rui Wang, Payal Deepak Shah, Joshua Z. Drago, Komal Jhaveri
Purpose:Activating mutations in PIK3CA promote resistance to HER2-targeted therapy in breast cancer; however, inhibition of PI3K alone leads to escape via feedback upregulation of HER3. Combined inhibition of HER2, HER3, and PI3K overcomes this mecha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69ae01f97661fac0629fd8d398512a0d
https://doi.org/10.1158/1078-0432.c.6530615
https://doi.org/10.1158/1078-0432.c.6530615
Autor:
Komal, Jhaveri, Joshua Z, Drago, Payal Deepak, Shah, Rui, Wang, Fresia, Pareja, Fanni, Ratzon, Alexia, Iasonos, Sujata, Patil, Neal, Rosen, Monica N, Fornier, Nancy T, Sklarin, Sarat, Chandarlapaty, Shanu, Modi
Publikováno v:
Clin Cancer Res
BACKGROUND: Activating mutations in PIK3CA promote resistance to HER2-targeted therapy in breast cancer, however inhibition of PI3K alone leads to escape via feedback upregulation of HER3. Combined inhibition of HER2, HER3 and PI3K overcomes this mec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::89eeec9e8a106422ff5b1077e16fd370
https://pubmed.ncbi.nlm.nih.gov/33947692
https://pubmed.ncbi.nlm.nih.gov/33947692
Autor:
Alyce Mei-Shiuan Kuo, Rachel E. Reingold, Kwami Ketosugbo, Alexander Pan, Stephen W Dusza, Lukas Kraehenbuehl, Devika Gajria, Diana E Lake, Jacqueline Bromberg, Shari Beth Goldfarb, Tiffany A. Traina, Monica N. Fornier, Ayca Gucalp, Megan Dauscher, Alina Markova, Mario E. Lacouture
Publikováno v:
Journal of Clinical Oncology. 40:12022-12022
12022 Background: Late alopecia is defined as incomplete hair regrowth > 6 months following cytotoxic chemotherapy or from initiation of endocrine therapy. It has been reported in up to 25-30% of cancer survivors and is associated with decreased qual
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3437c9d2ce0504b41f01a2ff52a2f5a2
https://doi.org/10.1200/jco.2022.40.16_suppl.12022
https://doi.org/10.1200/jco.2022.40.16_suppl.12022
Publikováno v:
Community Oncology. 9:S1-S4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ee85b8e5173829fce837188965d3b044
https://doi.org/10.1016/j.cmonc.2012.03.001
https://doi.org/10.1016/j.cmonc.2012.03.001
Publikováno v:
Community Oncology. 9:S13-S19
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2a532b719eff3456690e2e97f8f77f1
https://doi.org/10.1016/j.cmonc.2012.03.003
https://doi.org/10.1016/j.cmonc.2012.03.003
Autor:
Monica N. Fornier
Publikováno v:
Clinical Cancer Updates. 1:9-15
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a46cc7e1c45ff186f68a4ccb686ac4c3
https://doi.org/10.3816/ccu.2007.n.002
https://doi.org/10.3816/ccu.2007.n.002
Publikováno v:
Cancer. 104:1575-1579
BACKGROUND Twenty-five percent of all women with breast carcinoma are premenopausal and are at risk for chemotherapy-induced menopause with long-term side effects. Although there is considerable documentation of the rates of chemotherapy-induced amen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3e2f6f16bd6fdee0ce4d69495da583f
https://doi.org/10.1002/cncr.21385
https://doi.org/10.1002/cncr.21385